Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, primarily metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, efruxifermin (EFX), is an engineered analog of the hormone FGF21 designed to reverse liver fibrosis and cirrhosis while improving metabolic health. Akero’s business model centers on advancing EFX through clinical trials and eventual commercialization targeting patients with advanced liver disease and related metabolic conditions.
This description was generated via AI from an annual report. Updated about 1 year ago.